Vesugen (KED)

Vesugen (Lys-Glu-Asp, KED) is a synthetic tripeptide developed by Vladimir Khavinson's group as the vascular-targeted member of the peptide bioregulator family. It was derived from extracts of bovine vascular tissue, following the Khavinson paradigm that each organ produces characteristic short peptides that serve as endogenous bioregulators, and that supplementing these peptides can restore declining tissue function. Vesugen is the designated bioregulator for the vascular endothelium and smooth muscle.

The mechanism — shared conceptually across Khavinson bioregulators — involves direct peptide-DNA interaction: KED is hypothesized to penetrate vascular endothelial and smooth muscle cell nuclei and bind to specific DNA sequences in the promoter regions of genes involved in vascular homeostasis. In vitro, Vesugen has been shown to normalize endothelin-1 levels in atherosclerotic endothelial cultures (reducing the pathological vasoconstriction and inflammation driven by excess ET-1), restore connexin expression and gap-junction coupling between endothelial cells (critical for coordinated vasomotor responses), and stimulate the proliferation marker Ki-67 in aged vascular cells via proposed epigenetic activation of the MKI67 gene. A 2017 study (PMID 28539025) demonstrated that KED normalized atherosclerosis-elevated endothelin-1 and restored connexin 43 coupling in primary human endothelial cultures.

The vascular endothelium is a particularly compelling target for peptide bioregulation because endothelial dysfunction is a unifying feature of cardiovascular aging: it underlies hypertension, atherosclerosis, impaired tissue perfusion, and microvascular rarefaction. By targeting endothelial gene expression directly rather than individual downstream pathways (e.g., NO signaling, angiotensin, endothelin), Vesugen aims to restore a more coordinated, youthful pattern of vascular gene expression. However, the evidence base is small — three primary studies with direct Vesugen/KED data — and the proposed gene-regulatory mechanism remains a subject of scientific debate.

Vesugen was developed at the Saint Petersburg Institute of Bioregulation and Gerontology, likely in the 1990s–2000s as part of Khavinson's organ-by-organ bioregulator program. Compared to Epithalon and Thymalin — the most studied Khavinson peptides — Vesugen has a considerably thinner publication record, with only three primary studies that name the compound directly.

The most significant published data comes from a 2017 in vitro study (PMID 28539025) that demonstrated KED's effects on endothelin-1 and connexin expression in atherosclerotic endothelial cultures. Additional research has examined Vesugen's effects on Ki-67 proliferation markers in aged vascular cells. Clinical data is extremely limited — no randomized controlled trials have been conducted, and the compound has no regulatory approval outside of Russia. Within the Khavinson research community, Vesugen is typically studied as part of multi-bioregulator protocols rather than as a standalone intervention, often combined with Pinealon (cognitive + vascular) or Epithalon (telomerase + vascular) on the rationale that vascular health is foundational to organ function across all systems.

Store lyophilized Vesugen at -20°C in a light-protected, desiccated container. As a small tripeptide (Lys-Glu-Asp, molecular weight ~375 Da) with no disulfide bonds, it is structurally simple and relatively stable. The lysine residue's ε-amino group is the primary degradation vulnerability — protect from moisture to minimize deamidation and Maillard reactions. Stability exceeds 24 months under optimal conditions.

After reconstitution with bacteriostatic water, Vesugen should be refrigerated at 2–8°C and used within 21 days. The tripeptide is highly water-soluble — all three residues are charged at physiological pH (Lys +, Glu -, Asp -), giving it excellent aqueous solubility. The solution is clear and colorless. As with other Khavinson bioregulators, Vesugen is researched in 10–20 day cycles rather than continuously, with a 4–6 month interval between cycles. Do not freeze reconstituted solutions.